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Aims:We identiﬁed easily obtained baseline characteristics associated with outcomes in patients with chronic
heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in
the SHIFT trial, and used them to develop a prognostic model.
Methods:Weselected the 10 best predictors for each of four outcomes (cardiovascular death orHFhospitalisation;
all-cause mortality; cardiovascular mortality; and HF hospitalisation). All variables with p b 0.05 for association
were entered into a forward stepwise Cox regression model. Our initial analysis excluded baseline therapies,
though randomisation to ivabradine or placebo was forced into the model for the composite endpoint and HF
hospitalisation.
Results: Increased resting HR, low ejection fraction, raised creatinine, New York Heart Association class III/IV,
longer duration of HF, history of left bundle branch block, low systolic blood pressure and, for three models, age
were strong predictors of all outcomes. Additional predictors were low body mass index, male gender, ischaemic
HF, low total cholesterol, no history of hyperlipidaemia or dyslipidaemia and presence of atrial ﬁbrillation/ﬂutter.
The c-statistics for the four outcomes ranged from 67.6% to 69.5%. There was no evidence for lack of ﬁt of the
models with the exception of all-cause mortality (p = 0.017). Similar results were found including baseline
therapies.
Conclusion: The SHIFT RiskModel includes simple, readily obtainable clinical characteristics to produce important
prognostic information in patients with chronic HF, systolic dysfunction, and elevated HR. This may help better
calibrate management to individual patient risk.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
In patients with chronic systolic heart failure (HF), despite modern
pharmacological therapy, episodes of worsening heart failure (WHF)
are common, and history of previous hospitalisation further increases
the risk of subsequent admissions or death [1,2]. Recent European
Society of Cardiology (ESC) guidelines recommend ivabradine to im-
prove outcome for patients in sinus rhythm who remain symptomatic
with reduced left ventricular ejection fraction (LVEF) and heart rateatistics, University of Glasgow,
eliability and freedom from bias
land Ltd. This is an open access articl≥70 bpm despite other evidence-based therapies, including beta-
blocker [3]. This recommendation is based on the results of SHIFT (Sys-
tolic Heart failure treatment with the If inhibitor ivabradine Trial), in
which the patients enrolled had a hospital admission during the year
preceding the trial enrolment.
Advances in therapies for HF create a continuous need for the con-
struction of newmodels in contemporary HF trials. Objective prognostic
information could guide decision-making in the management of HF in
all or subsets of patients. Risk models also have a value in economic
evaluations for projecting the potential beneﬁt of a therapy that
prevents non-fatal events and in identifying subgroups where the eco-
nomic impact is greatest. Similarly, risk stratiﬁcation can provide the
opportunity to explore potential interactions between underlying risk
and treatment effect. In some contexts, estimation of risk can be used
to target individuals for more intensive monitoring and therapy. HFe under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of the study population.
Baseline characteristic N with data Value
Age (years) 6505 60.9 ± 11.4
Male 6505 4970 (76.4%)
Body mass index (kg/m2) 6504 25.8 ± 2.4
Cardiac parameters
Heart rate (bpm) 6501 79.9 ± 9.6
Systolic blood pressure (mm Hg) 6505 121.7 ± 16.0
Diastolic blood pressure (mm Hg) 6505 75.7 ± 9.5
Left ventricular ejection fraction (%) 6505 29.0 ± 5.2
Laboratory parameters
eGFR (mL/min per 1.73 m2) 6485 74.6 ± 22.9
Serum creatinine (μmol/L) 6485 96.7 ± 26.4
Anaemia (Hb ≤120 g/L) 6483 550 (8.5%)
ALT (U/L) 6470 25.4 ± 14.9
Total cholesterol ≤3.4 mmol/L 6505 637 (9.8%)
Total cholesterol 3.41 to b4.8 mmol/L 6505 2032 (31.2%)
Total cholesterol ≥4.9 mmol/L 6505 3836 (59.0%)
Potassium b4.2 mmol/L 6435 1394 (21.7%)
Potassium 4.2 to 4.4 mmol/L 6435 1460 (22.7%)
Potassium 4.5 to 4.8 mmol/L 6435 1969 (30.6%)
Potassium ≥4.9 mmol/L 6435 1612 (25.1%)
Sodium (mmol/L) 6455 140.5 ± 3.6
Medical history
NYHA class III/IV vs class II 6503 3334 (51.3%)
Heart failure duration (years) 6505 41.9 ± 50.4
Ischaemic heart failure 6505 4418 (67.9%)
History of myocardial infarction 6505 3666 (56.4%)
History of hypertension 6505 4314 (66.3%)
History of diabetes 6505 1979 (30.4%)
History of stroke 6505 523 (8.0%)
Atrial ﬁbrillation/ﬂutter 6505 522 (8.0%)
Prior coronary surgery 6505 886 (13.6%)
History of hyperlipidaemia/dyslipidaemia 6505 1890 (29.1%)
History of chronic obstructive pulmonary disease 6505 730 (11.2%)
History of left bundle branch block 6505 912 (14.0%)
Treatments
Beta-blocker 6505 5820 (89.5%)
Angiotensin-converting enzyme inhibitor 6505 5116 (78.6%)
Cardiac glycosides 6505 1416 (21.8%)
Angiotensin II receptor blocker 6505 927 (14.3%)
Diuretic 6505 5414 (83.2%)
Antiarrhythmic agent 6505 197 (3.0%)
Mineralocorticoid receptor antagonist 6505 3922 (60.3%)
Vitamin K antagonist 6505 1082 (16.6%)
Lipid-lowering medication 6505 3794 (58.3%)
CRT device 6505 72 (1.1%)
ICD device 6505 207 (3.2%)
Ivabradine treatment 6505 3241 (49.8%)
Values are means ± SD or numbers (%). NYHA = New York Heart Association. eGFR =
estimated glomerular ﬁltration rate (modiﬁcation in diet in renal disease formula). CRT =
cardiac resynchronisation therapy. ICD = implantable cardioverter deﬁbrillator.
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measurements. Some have argued that relatively simple risk scores,
not needing computers, are needed [4]. However, with the growth in
the use of electronic patient records and the universal availability of
handheld devices capable of complex calculations, this argument no
longer seems tenable. On the other hand, there are advantages in scores
that utilize a modest number of readily available risk factors as well as
more complex models.
Recent approaches to developing riskmodels in HF include that pub-
lished by the CHARM (Candesartan in Heart failure: Assessment of
Reduction in Mortality and morbidity) investigators [5] and Seattle
Heart Failure Model [6], which evaluates factors prognostic for HF and
was developed and validated in independent cohorts. The MAGGIC
(Meta-analysis Global Group in Chronic Heart Failure) collaborators
have also recently developed a risk model for all-cause mortality
based on 39,372 patients from a group of HF trials and registries con-
ducted over a long period of time [7]. However, this approach has
been a subject of debate because it includes a heterogeneous group of
patients many of whom were recruited when heart failure treatment
did not include all the modalities commonly used day.
The aim of the present study was to investigate the risk for the out-
comes of death from all causes, death from cardiovascular causes, and
death and/or hospitalisation for HF in symptomatic patients in sinus
rhythm with chronic HF, left ventricular systolic dysfunction (LVSD)
and heart rate ≥70 bpm (a level known to be a risk descriptor in HF),
in whom therapy with ivabradine might be considered. Analyses are
based on data from the Systolic Heart failure treatmentwith the If inhib-
itor ivabradine Trial (SHIFT).
2. Methods
2.1. SHIFT study design
SHIFT was a randomised, double-blind, placebo-controlled trial in
patients with moderate to severe HF and LVSD. The study design has
been described in detail previously [8,9]. SHIFT included patients with
symptomatic HF stable for at least 4 weeks, who had a hospitalisation
due to WHF within the past 12 months, were in sinus rhythm with a
resting frequency ≥70 bpm, and had an LVEF ≤35%. A total of 6505
patients were randomised and received ivabradine, a sinus node inhib-
itor, or placebo, on top of standard HF therapy. Median follow-up in the
SHIFT trial was 22.9 (IQR 18–28) months. Hospitalisation for WHF dur-
ing follow-up was deﬁned as an admission with new or increasing
symptoms and signs of HF including ﬂuid retention or other objective
evidence of HF, in combination with a change in treatment to improve
HF. An endpoint validation committee adjudicated all pre-speciﬁed
events including HF and cardiovascular death. All patients provided
written informed consent for their participation in the study. The
study complies with the Declaration of Helsinki and was approved by
ethics committees in all participating countries.
2.2. Statistical methods
We reviewed baseline data collected in the SHIFT trial and identiﬁed
all variables that could potentially be associated with adverse clinical
outcomes (Table 1). In addition to demographic information, medical
history, and basic measurements, we included laboratory measure-
ments and baseline cardiovascular medications. The analysis focuses
on the 6390 participants who had complete baseline data.
We studied four outcomes, namely a composite of cardiovascular
death or hospital admission for HF (the primary outcome of SHIFT),
all-cause mortality, cardiovascular mortality, and hospital admission
for HF. All analyses are based on the time from randomisation until
the ﬁrst outcome for each endpoint or end of study, whichever came
ﬁrst. Follow-up was censored at time of death for deaths not included
in the outcome analysed. Analyses were based on Cox proportionalhazardmodels.We ﬁrst reviewed all continuous risk factors univariately
to assess whether or not there was evidence of a non-linear relationship
with risk of each outcome. Variables were then included in the analysis
as continuous variables or were categorised by tertiles or quartiles of
their distribution as appropriate. As was done in the models ﬁtted for
the CHARM trials [5], all patients under the age of 60 years were
assigned the same risk and a linear continuous relationship was
assumed above the age of 60 years. A similar approach was adopted
for body mass index (BMI) where the same risk was assumed for all
BMI N 27.5 kg/m2, with a continuous relationship below 27.5 kg/m2.
Two strategies for risk modelling were used (Appendix A). In the
ﬁrst approach, we selected the top 10 best predictors for each outcome,
in addition to randomised treatment allocation in the case of cardiovas-
cular death or hospitalisation for HF. We excluded randomised treat-
ment for other outcomes as there was no signiﬁcant association of
randomised treatment with mortality outcomes. On the basis of the
univariate Cox models, all variables with p b 0.05 for association for a
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model analysis with p b 0.05 to enter the model, with the exception
that randomised allocation to ivabradine or placebo was forced into
the models for cardiovascular death or hospitalisation for HF and
hospitalisation for heart failure. We ﬁtted models both including
and excluding baseline therapies (drugs and devices). This provided
two models for each outcome.
In the second approach, we adopted a similar strategy, but allowed
all variables to potentially enter themodels without a limit on the num-
ber of variables in the model. This provided a further two models for
each outcome. Results for the best 10 predictors are provided in the
mainmanuscript (ﬁrst approach) and for the largermodels in Appendix
B (second approach).
To assess the ability of the models to discriminate between patients
who do and do not have events, we calculated c-statistics. To measure
goodness of ﬁt of our models, we ﬁrst calculated outcome-speciﬁc risk
scores for each subject and used these to assign the patients to 10 cate-
gories based on deciles of their risk scores. The categorical variables
associated with the 10 subgroups were then added to each ﬁtted risk
model and a Wald test for the added terms was computed as a lack-
of-ﬁt test. The observed andpredicted numbers of events in the ten sub-
groups were compared graphically using bar charts (results only for the
models including baseline therapies are presented in the paper).
Finally, for the primary outcome, a risk model was developed
excluding randomised treatment group. All patients were then assigned
to ﬁve subgroups on the basis of quintiles of their estimated baseline
risk scores. The effect of ivabradine treatment compared to placebo
was then evaluated within each subgroup and then compared across
subgroups in a Cox regression model to test for evidence of an interac-
tion between treatment and underlying risk using a trend test. A
description of the calculations involved in deriving risk probabilities is
given in Appendix A.
Statistical analyses were performed by the Robertson Centre for
Biostatistics (Glasgow, UK) using SAS (version 9.2).
3. Results
Baseline characteristics for potential risk factors are given in Table 1.
Univariable associations of each potential risk factor with each of the
four outcomes studied are given in Table 2. The patterns of associations
are almost identical for all-cause and cardiovascular mortality, with all
factors being associated with outcome, with the exception of device
use, ACE inhibitor, and vitamin K antagonist use, and a history of diabe-
tes; there were only weak associations for ARB use, prior coronary sur-
gery, and ischaemic HF. Associations with the primary outcome and HF
hospitalisationwere broadly similar. However for these outcomes, there
was no association with gender, no or weaker associations with history
of ischaemic HF or myocardial infarction, hypertension, and hyperlipid-
aemia/dyslipidaemia, and stronger associations with ACE inhibitor use,
vitamin K antagonist use, and use of devices.
The top 10 predictors of outcomes in the models excluding baseline
therapies are given in Table 3. Increased heart rate, low LVEF, raised cre-
atinine, being in NYHA class III/IV, longer duration of HF, increased age
(with the exception of cardiovascular mortality), history of left bundle
branch block and low systolic blood pressure were strong predictors
for all four outcomes. Additional predictors of outcome were low BMI
for all-cause and cardiovascular mortality, male gender for all-cause
mortality, ischaemic HF for cardiovascular mortality, lower levels of
cholesterol for the primary outcome and HF hospitalisation, a history
of atrial ﬁbrillation/ﬂutter for primary outcome, and diabetes or lack
of history of hyperlipidaemia/dyslipidaemia for HF hospitalisation. The
c-statistics for the four outcomes in Table 3 ranged from 67.6% to
69.5%. There was no evidence for lack of ﬁt for the primary outcome,
cardiovascular mortality, or HF hospitalisation (p = 0.10, p = 0.54,
and p = 0.07, respectively). However there was some evidence for
lack of ﬁt for the model predicting all-cause mortality (p = 0.017).The top 10 predictors of outcomes in the model including baseline
therapies are given in Table 4. For the primary outcome and HF
hospitalisation, compared to the model excluding baseline therapies,
systolic blood pressure and atrial ﬁbrillation/ﬂutter dropped out of the
model to be replaced by treatment with cardiac glycosides and MRAs.
For all-cause mortality, history of left bundle branch block and male
gender dropped out to be replaced by history of ischaemic HF and treat-
ment with cardiac glycosides. For cardiovascular mortality, systolic
blood pressure and history of left bundle branch block dropped out to
be replaced by treatment with cardiac glycosides, MRAs, and not being
treated with lipid-lowering agents. The c-statistics increased slightly
ranging from 68.2% to 70.2% (Table 4). For these models, there was no
evidence of lack of ﬁt for the all-cause and cardiovascular mortality
models (p= 0.11 and p= 0.47, respectively), while there was evidence
of lack of ﬁt for the primary outcome and HF hospitalisation (p = 0.005
and p b 0.0001, respectively).
Similar results were found in the approach using all variables to the
approach including the top 10 predictors, with the exception that inclu-
sion of additional predictors resulted in no evidence of lack of ﬁt for the
models incorporating baseline therapies. The corresponding results are
presented Appendix B.
Comparisons of the predicted numbers of events (percentage event
rate) with the actual numbers of events observed in the SHIFT trial are
illustrated for the four outcomes in the model including baseline thera-
pies in Fig. 1. Fig. 2 shows Kaplan–Meier time to primary outcome plots
for the estimated treatment effects of ivabradine or placebo for the
study participants split into ﬁfths of baseline risk. There is no evidence
of an interaction between beneﬁt and riskwith clear evidence of beneﬁt
in both the lowest and highest ﬁfths of the distribution of risk (Fig. 3).
4. Discussion
Our SHIFT Risk Model was constructed from an analysis in patients
with systolic HF in sinus rhythm with high levels of the use of current
evidence-based medical therapy (79% ACE inhibitors, 14% ARBs, 90%
beta-blockers, and 60% mineralocorticoid receptor antagonists) [10].
The parameters in the model are all easy to obtain in routine clinical
practice or with simple laboratory tests, and the result is a model that
is reasonably good at predicting mortality and morbidity outcomes
over 2 years (c-statistic, 67.6% to 69.5%). The best predictors of poor
prognosis were resting heart rate, LVEF, creatinine, BMI, NYHA class,
duration of HF, age, SBP, history of left bundle branch block, male sex,
ischaemic HF, total cholesterol, and history of atrial ﬁbrillation/ﬂutter.
The role of elevated resting heart rate in predicting morbidity and
mortality outcomes in patients with systolic HF is well established,
and there is a progressive rise in risk as resting heart rate rises above
70 bpm [11,12]. In the SHIFT population, which, by deﬁnition, already
had a resting heart rate ≥70 bpm, every 10-bpm increase in resting
heart rate was associated with a 31% increase in the primary composite
endpoint, a 26% increase in all-causemortality, a 27% increase in cardio-
vascular mortality, and a 32% increase in HF hospitalisation. As an
important component of risk, therefore, resting heart rate was also an
important parameter in the risk model.
Our analysis also conﬁrms the importance of conventional HF risk
factors. Poor outcomes are expected to bemore likely in the very elderly
and, accordingly, we found that a 10-year increase over the age of
60 years increased the risk for primary composite endpoint by 24%,
all-cause mortality by 29%, and HF hospitalisation by 25%. Whether
this increase in risk with age is due to greater severity, increasing num-
ber of unmeasured comorbidities, or discrepancies in care of elderly HF
patients remains unclear [13]. In this context, we also found that pa-
tients with long-standing disease were at 7% to 9% higher risk for all
four outcomes for each 2 years they have lived with HF. Measures of
severity of congestive HF also came out as strong predictors in the
SHIFT Risk Model. NYHA class constitutes a clinical measure of symp-
tomatic severity and is known to be a strong predictor of survival in
Table 2
Univariable associations of baseline factors with risk for primary endpoint, all-cause mortality, cardiovascular mortality, and heart failure (HF) hospitalisation.
Baseline characteristic Primary outcome All-cause mortality Cardiovascular mortality HF hospitalisation
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Age (10 years over 60 years) 1.32 (1.24–1.41) b0.001 1.34 (1.23–1.45) b0.001 1.30 (1.19–1.42) b0.001 1.33 (1.23–1.44) b0.001
Male 1.11 (0.99–1.24) 0.085 1.37 (1.18–1.61) b0.001 1.34 (1.14–1.58) b0.001 0.99 (0.86–1.13) 0.84
Body mass index (1 kg/m2 below 27.5 kg/m2) 1.07 (1.05–1.09) b0.001 1.10 (1.07–1.12) b0.001 1.10 (1.07–1.13) b0.001 1.05 (1.03–1.08) b0.001
Cardiac parameters
Heart rate (10-bpm increase) 1.32 (1.27–1.38) b0.001 1.29 (1.22–1.36) b0.001 1.29 (1.22–1.37) b0.001 1.35 (1.28–1.42) b0.001
SBP (10-mm Hg decrease) 1.14 (1.10–1.17) b0.001 1.18 (1.13–1.23) b0.001 1.19 (1.14–1.24) b0.001 1.15 (1.11–1.20) b0.001
DBP (10-mm Hg decrease) 1.19 (1.13–1.25) b0.001 1.24 (1.17–1.33) b0.001 1.24 (1.16–1.33) b0.001 1.22 (1.15–1.30) b0.001
LVEF (5% decrease) 1.30 (1.25–1.36) b0.001 1.31 (1.24–1.38) b0.001 1.32 (1.25–1.40) b0.001 1.35 (1.28–1.42) b0.001
Laboratory parameters
eGFR (10-unit decrease) 1.11 (1.08–1.13) b0.001 1.10 (1.07–1.13) b0.001 1.10 (1.07–1.13) b0.001 1.13 (1.10–1.16) b0.001
Creatinine (10-unit increase) 1.09 (1.07–1.11) b0.001 1.10 (1.08–1.12) b0.001 1.10 (1.08–1.12) b0.001 1.09 (1.07–1.11) b0.001
Anaemic (Hb ≤120 g/L) 1.58 (1.37–1.84) b0.001 1.60 (1.33–1.92) b0.001 1.51 (1.24–1.85) b0.001 1.73 (1.45–2.05) b0.001
ALT (per 10 unit decrease) 1.08 (1.05–1.12) b0.001 1.09 (1.04–1.15) b0.001 1.10 (1.04–1.15) b0.001 1.08 (1.04–1.13) b0.001
Total cholesterol: ≤3.4 vs ≥4.5 mmol/L 1.51 (1.30–1.75) b0.001 1.42 (1.17–1.72) 0.001 1.39 (1.14–1.71) 0.005 1.73 (1.46–2.06) b0.001
Total cholesterol: 3.41–4.49 vs ≥4.5 mmol/L 1.14 (1.02–1.26) 1.11 (0.97–1.27) 1.11 (0.97–1.28) 1.23 (1.09–1.40)
Potassium b4.2 vs ≥4.9 mmol/L 1.04 (0.91–1.19) b0.001 0.99 (0.83–1.18) 0.006 1.01 (0.84–1.21) 0.002 1.03 (0.88–1.21) 0.003
Potassium 4.2–4.4 vs ≥4.9 mmol/L 0.73 (0.63–0.84) 0.74 (0.62–0.89) 0.72 (0.59–0.87) 0.75 (0.63–0.90)
Potassium 4.5–4.8 vs ≥4.9 mmol/L 0.91 (0.80–1.03) 0.89 (0.76–1.04) 0.87 (0.74–1.03) 0.93 (0.80–1.08)
Sodium (per 1 unit decrease) 1.04 (1.02–1.05) b0.001 1.05 (1.03–1.06) b0.001 1.04 (1.03–1.06) b0.001 1.05 (1.03–1.06) b0.001
Medical history
NYHA class III/IV vs II 1.68 (1.52–1.85) b0.001 1.63 (1.44–1.85) b0.001 1.71 (1.50–1.96) b0.001 1.71 (1.52–1.92) b0.001
HF duration (2 years increase) 1.09 (1.07–1.11) b0.001 1.08 (1.06–1.11) b0.001 1.09 (1.07–1.12) b0.001 1.09 (1.07–1.12) b0.001
Ischaemic heart failure 1.09 (0.98–1.21) 0.11 1.16 (1.01–1.32) 0.032 1.19 (1.03–1.37) 0.017 1.01 (0.89–1.14) 0.91
Myocardial infarction 1.12 (1.02–1.24) 0.019 1.18 (1.04–1.33) 0.009 1.24 (1.08–1.41) 0.002 1.03 (0.92–1.15) 0.63
Hypertension 0.91 (0.82–1.00) 0.051 0.86 (0.76–0.97) 0.016 0.82 (0.72–0.93) 0.003 0.90 (0.80–1.01) 0.080
Diabetes 1.23 (1.11–1.35) b0.001 1.12 (0.99–1.28) 0.073 1.07 (0.94–1.23) 0.31 1.32 (1.17–1.48) b0.001
Stroke 1.43 (1.23–1.67) b0.001 1.48 (1.23–1.79) b0.001 1.42 (1.16–1.74) b0.001 1.42 (1.18–1.71) b0.001
Atrial ﬁbrillation/ﬂutter 1.40 (1.20–1.63) b0.001 1.30 (1.07–1.58) 0.009 1.24 (1.00–1.54) 0.046 1.47 (1.23–1.76) b0.001
Prior coronary surgery 1.03 (0.90–1.18) 0.71 1.14 (0.99–1.32) 0.063 1.17 (1.01–1.36) 0.042 1.17 (1.00–1.37) 0.047
History of hyperlipidaemia/dyslipidaemia 0.87 (0.78–0.96) 0.009 0.73 (0.64–0.85) b0.001 0.74 (0.64–0.86) 0.001 0.93 (0.82–1.05) 0.25
Chronic obstructive pulmonary disease 1.55 (1.36–1.77) b0.001 1.38 (1.16–1.63) b0.001 1.31 (1.09–1.57) 0.004 1.71 (1.46–1.99) b0.001
History of LBBB 1.65 (1.47–1.86) b0.001 1.49 (1.28–1.74) b0.001 1.49 (1.26–1.75) b0.001 1.86 (1.63–2.14) b0.001
Treatments
Beta-blocker 0.69 (0.60–0.79) b0.001 0.61 (0.51–0.72) b0.001 0.62 (0.52–0.74) b0.001 0.69 (0.58–0.81) b0.001
Angiotensin-converting enzyme inhibitor 0.86 (0.77–0.97) 0.011 0.97 (0.83–1.12) 0.64 0.99 (0.84–1.16) 0.87 0.80 (0.70–0.92) 0.001
Cardiac glycosides 1.77 (1.60–1.97) b0.001 1.72 (1.51–1.97) b0.001 1.79 (1.56–2.06) b0.001 1.91 (1.69–2.16) b0.001
Angiotensin II receptor blocker 1.06 (0.92–1.21) 0.42 0.82 (0.68–0.99) 0.043 0.80 (0.65–0.98) 0.029 1.17 (1.00–1.37) 0.045
Diuretic 1.75 (1.51–2.04) b0.001 1.38 (1.15–1.65) b0.001 1.45 (1.19–1.76) b0.001 2.15 (1.76–2.62) b0.001
Antiarrhythmic medication 1.66 (1.33–2.08) b0.001 1.69 (1.28–2.22) b0.001 1.65 (1.23–2.21) b0.001 1.68 (1.28–2.19) b0.001
Mineralocorticoid receptor antagonist 1.55 (1.40–1.72) b0.001 1.49 (1.30–1.69) b0.001 1.58 (1.38–1.82) b0.001 1.61 (1.42–1.82) b0.001
Vitamin K antagonist 1.32 (1.18–1.49) b0.001 1.11 (0.95–1.29) 0.21 1.13 (0.96–1.33) 0.14 1.39 (1.21–1.60) b0.001
Lipid-lowering medication 0.76 (0.69–0.83) b0.001 0.70 (0.62–0.79) b0.001 0.68 (0.60–0.78) b0.001 0.76 (0.67–0.85) b0.001
CRT 1.95 (1.37–2.79) b0.001 0.73 (0.37–1.47) 0.38 0.62 (0.28–1.38) 0.24 2.75 (1.92–3.96) b0.001
ICD 1.57 (1.24–1.98) b0.001 0.85 (0.58–1.25) 0.42 0.85 (0.57–1.27) 0.43 2.22 (1.75–2.83) b0.001
Ivabradine treatment 0.82 (0.75–0.90) b0.001 0.91 (0.80–1.02) 0.11 0.91 (0.80–1.03) 0.15 0.75 (0.66–0.84) b0.001
HR=hazard ratio. CI= conﬁdence interval. SBP= systolic blood pressure. DBP=diastolic blood pressure. LVEF= left ventricular ejection fraction. NYHA=NewYork Heart Association.
eGFR = estimated glomerular ﬁltration rate. CRT = cardiac resynchronisation therapy. ICD = Implantable cardioverter deﬁbrillator.
166 I. Ford et al. / International Journal of Cardiology 184 (2015) 163–169HF [3]. Indeed, in our study, being in NYHA class III/IV, i.e. having mod-
erate to severe symptoms, was associatedwith a 43% increase in risk for
the SHIFT primary composite endpoint versus those who were only
mildly symptomatic (NYHA class II). Worsening myocardial function,
as recorded by decreased LVEF, is known to predict morbidity andmor-
tality endpoints [14]. In linewith this, we found that a reduction of LVEF
by 5% led to a 20% increase in risk for the primary composite endpoint.
The inverse relationship between BMI and prognosis in HF is well
known, and the so-called “obesity paradox,” by which decreased BMI
is associated with poorer outcomes in HF in contrast to the situation
in CAD, has beenwidely discussed in the literature [15–17]. Similar par-
adoxical relationships are observed for blood pressure and total choles-
terol [17–19], insofar as low SBP and/or serum lipoprotein levels are
associated with substantially greater risk in HF. Our results are totally
in line with this.
Meta-analyses have indicated that renal dysfunction confers a sub-
stantially higher risk of mortality than thosewith normal renal function
[20,21]. An increase in creatinine by 10 units was found to be predictive
of primary endpoint (6% increase in risk) in the SHIFT Risk Model. Leftbundle branch block and history of atrial ﬁbrillation are also known to
affect prognosis in patients with HF [22,23]. Accordingly, we found
that the presence of one of these conditions in the SHIFT population
was an important contributor of increased risk for the primary outcome.
This is in linewith theﬁndings from the CHARMdatabase, inwhich atri-
al ﬁbrillation was a predictor of outcome, particularly for HF with pre-
served ejection fraction [24].
In our study, ischaemic aetiology was predictive of mortality out-
comes, but not for HF hospitalisation. By contrast, diabetes was predic-
tive only for HF hospitalisation, but not mortality outcomes, and being
on ACE inhibitor was univariately associated with lower risk of HF
hospitalisation but not mortality; this association was lost in multivari-
ate analysis. Possible explanations for differences when compared to
other studies include the more homogeneous cohort recruited in
SHIFT, notably since the patients had a relatively high heart rate and
higher rates of usage of guideline-recommended cardiovascular medi-
cations than patients recruited in other trials.
A number or riskmodels have been developed in HF [5–7,16,25–27].
Although all the models are helpful, their performance is inconsistent
Table 3
Top 10 multivariable predictors of each of primary composite outcome, all-cause mortality, cardiovascular mortality, and heart failure (HF) hospitalisation (approach excluding baseline
therapies).
Baseline characteristic Primary outcome Cardiovascular mortality HF hospitalisation
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Randomised treatment 0.83 (0.75–0.91) b0.001 – – 0.74 (0.66–0.83) b0.001
Heart rate (10-bpm increase) 1.31 (1.25–1.36) b0.001 1.26 (1.20–1.34) b0.001 1.25 (1.18–1.33) b0.001 1.32 (1.26–1.40) b0.001
LVEF (5% decrease) 1.20 (1.15–1.26) b0.001 1.19 (1.13–1.26) b0.001 1.22 (1.15–1.30) b0.001 1.23 (1.17–1.29) b0.001
Creatinine (10-unit increase) 1.06 (1.04–1.08) b0.001 1.07 (1.05–1.10) b0.001 1.09 (1.07–1.12) b0.001 1.06 (1.04–1.08) b0.001
BMI (1-kg/m2 decrease below 27.5 kg/m2) – 1.06 (1.04–1.09) b0.001 1.07 (1.04–1.10) b0.001 –
NYHA class III/IV vs II 1.43 (1.30–1.59) b0.001 1.40 (1.23–1.59) b0.001 1.44 (1.25–1.65) b0.001 1.42 (1.26–1.61) b0.001
Duration of heart failure (2-year increase) 1.07 (1.05–1.09) b0.001 1.07 (1.04–1.09) b0.001 1.09 (1.06–1.11) b0.001 1.08 (1.05–1.10) b0.001
Age (10-year increase over age 60) 1.24 (1.15–1.33) b0.001 1.29 (1.17–1.41) b0.001 – 1.25 (1.15–1.37) b0.001
SBP (10-mm Hg decrease) 1.10 (1.06–1.13) b0.001 1.12 (1.08–1.17) b0.001 1.13 (1.08–1.18) b0.001 1.11 (1.07–1.15) b0.001
History of left bundle branch block 1.43 (1.27–1.62) b0.001 1.28 (1.10–1.50) 0.002 1.29 (1.09, 1.52) 0.003 1.63 (1.42–1.88) b0.001
Male – 1.43 (1.21–1.68) b0.001 – –
Ischaemic heart failure – – 1.39 (1.20–1.62) b0.001 –
Total cholesterol ≤3.4 vs ≥4.5 mmol/L 1.42 (1.22–1.66) b0.001 – – 1.57 (1.31–1.88) b0.001
Total cholesterol 3.41-4.49 vs ≥4.5 mmol/L 1.11 (1.00–1.23) – – 1.20 (1.05–1.36)
Atrial ﬁbrillation/ﬂutter 1.35 (1.15–1.57) b0.001 – – –
Diabetes – – – 1.26 (1.12–1.43) b0.001
History of hyperlipidaemia/dyslipidaemia – – 0.77 (0.66–0.90) b0.001
c-Statistic 67.6% 67.7% 68.3% 69.5%
p (lack of ﬁt) 0.10 0.017 0.54 0.07
Dashes (–) reﬂect variables not included in themodel. HR=hazard ratio. CI= conﬁdence interval. BMI= bodymass index. LVEF= left ventricular ejection fraction. SBP= systolic blood
pressure. NYHA = New York Heart Association.
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over, insofar as the use of contemporary therapies may affect the
utility of the models, there is a need for models constructed in contem-
porary environments using parameters that are easily measured at the
bedside [28]. The SHIFT Risk Score constitutes a simple solution for
patient with higher heart rates, and is now accessible on the internet
(www.shift-study.com), with full details of the computation of risk
probabilities so that these can readily be programmed into local clin-
ical systems. Our ﬁndings can therefore be used in routine clinical
practice to provide a measure of the mortality risk for the individual
patient.
The main limitation to our study is that it is restricted by the proﬁle
of the patients included in the SHIFT trial, i.e. patientswith chronic HF inTable 4
Top 10 multivariable predictors of the primary outcome, all-cause mortality, cardiovascular mo
Baseline characteristic Primary outcome All-cause
HR (95% CI) p value HR (95%
Randomised treatment 0.81 (0.74–0.89) b0.001 –
Heart rate (10-bpm increase) 1.29 (1.24–1.35) b0.001 1.26 (1.1
Ejection fraction (5% decrease) 1.19 (1.14–1.24) b0.001 1.21 (1.1
Creatinine (10-unit increase) 1.07 (1.05–1.09) b0.001 1.08 (1.0
BMI (1-kg/m2 decrease below 27.5 kg/m2) – 1.06 (1.0
NYHA class III/IV vs II 1.40 (1.27–1.55) b0.001 1.34 (1.1
Duration of heart failure (2-year increase) 1.07 (1.05–1.09) b0.001 1.07 (1.0
Age (10-year increase over age 60) 1.28 (1.19–1.37) b0.001 1.24 (1.1
SBP (10-mm Hg decrease) – 1.12 (1.0
History of left bundle branch block 1.38 (1.22–1.56) b0.001 –
Male – –
Ischaemic heart failure – 1.36 (1.1
Total cholesterol ≤3.4 vs ≥4.5 mmol/L 1.46 (1.26–1.70) b0.001 –
Total cholesterol 3.41-4.49 vs ≥4.5 mmol/L 1.14 (1.03–1.27) –
Atrial ﬁbrillation/ﬂutter – –
Cardiac glycosides 1.45 (1.30–1.62) b0.001 1.51 (1.3
Mineralocorticoid receptor antagonist 1.41 (1.27–1.57) b0.001 –
Lipid-lowering medication – –
c-Statistic 68.3% 68.2%
P (lack of ﬁt) 0.005 0.11
Dashes (–) reﬂect variables not included in themodel. HR=hazard ratio. CI= conﬁdence inter
pressure. NYHA = New York Heart Association.sinus rhythm and with a resting heart rate ≥70 bpm. The model can
predict outcomes over 2 years, i.e. the duration of the SHIFT follow-up,
extrapolation beyond the SHIFT-type patient and longer follow-up
may be unreliable. A number of potentially important variables are
missing from the model, such as N-terminal pro-brain natriuretic pep-
tide, since the data were not available. Incorporation of such informa-
tion is likely to improve the goodness of ﬁt of the models for the
primary outcome and hospitalisation for HF. However, we note that
the goodness of ﬁt for predicting these outcomes was signiﬁcantly
improved in the more complex models presented in Appendix B. We
have not yet tested the risk model outside the realms of the SHIFT pop-
ulation. Prospective validation in other populations would provide im-
portant additional information.rtality, and heart failure (HF) hospitalisation (approach including baseline therapies).
mortality Cardiovascular mortality HF hospitalisation
CI) p value HR (95% CI) p value HR (95% CI) p value
– 0.73 (0.65–0.82) b0.001
9–1.34) b0.001 1.24 (1.17–1.31) b0.001 1.31 (1.24–1.38) b0.001
4–1.28) b0.001 1.23 (1.16–1.30) b0.001 1.21 (1.15–1.27) b0.001
6–1.11) b0.001 1.10 (1.08–1.13) b0.001 1.07 (1.05–1.09) b0.001
3–1.09) b0.001 1.08 (1.05–1.10) b0.001 –
8–1.53) b0.001 1.36 (1.19–1.56) b0.001 1.40 (1.24–1.58) b0.001
4–1.09) b0.001 1.09 (1.06–1.11) b0.001 1.08 (1.05–1.10) b0.001
3–1.36) b0.001 – 1.28 (1.18–1.40) b0.001
7–1.17) b0.001 – –
– 1.55 (1.35–1.79) b0.001
– –
7–1.57) b0.001 1.64 (1.40–1.93) b0.001 –
– 1.69 (1.41–2.01) b0.001
– 1.25 (1.10–1.42)
– –
1–1.73) b0.001 1.47 (1.27–1.70) b0.001 1.52 (1.34–1.73) b0.001
1.42 (1.23–1.64) b0.001 1.44 (1.27–1.64) b0.001
0.71 (0.62–0.82) b0.001 –
69.0% 70.2%
0.47 b0.001
val. BMI= bodymass index. LVEF= left ventricular ejection fraction. SBP= systolic blood
Fig. 1.Observed and predicted risk for primary outcome (A), all-causemortality (B), cardiovascularmortality (C), and heart failure (HF) hospitalisation (D) by tenths of the distribution of
predicted risk (approach excluding baseline therapies).
168 I. Ford et al. / International Journal of Cardiology 184 (2015) 163–169In conclusion, a risk model using simple, readily obtainable clinical
characteristics can provide important prognostic information in pa-
tients with chronic HF and systolic dysfunction. The SHIFT Risk Models
provide valuable information for clinical decision-making and can sup-
port the delivery of appropriate therapy to the patients for whom the
beneﬁts are likely to be the greatest.Funding
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